Tests volrustomig after chemoradiotherapy in head and neck cancer
Tests volrustomig against observation in adults with advanced head and neck cancer.
Plain-language title generated from the registry record
Registry title: A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
Key facts
- Where
- Bunkyō City, Chiba, Chūōku, Fukuoka, Hidaka-shi, Hiroshima, Kashiwa, Kobe, Kōtoku, Kyoto, Nagoya, Niigata, Okayama, Osaka, Osakasayama-shi, Sagamihara-shi, Sapporo, Sendai, Shinjuku-ku, Shiwa-gun, Sunto-gun, and Yokohama, JapanSee the 22 sites
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 130 years old?
Source: NCT06129864, who can take part
Where in Japan
- Bunkyō CityBunkyō City, JapanTaking people
- ChibaChiba, JapanTaking people
- ChūōkuChūōku, JapanTaking people
- FukuokaFukuoka, JapanTaking people
- Hidaka-shiHidaka-shi, JapanTaking people
- HiroshimaHiroshima, JapanTaking people
- KashiwaKashiwa, JapanTaking people
- KobeKobe, JapanTaking people
- KōtokuKōtoku, JapanTaking people
- KyotoKyoto, JapanTaking people
- NagoyaNagoya, JapanTaking people
- NiigataNiigata, JapanTaking people
- OkayamaOkayama, JapanTaking people
- OsakaOsaka, JapanTaking people
- Osakasayama-shiOsakasayama-shi, JapanTaking people
- Sagamihara-shiSagamihara-shi, JapanTaking people
- SapporoSapporo, JapanTaking people
- SendaiSendai, JapanTaking people
- Shinjuku-kuShinjuku-ku, JapanTaking people
- Shiwa-gunShiwa-gun, JapanTaking people
- Sunto-gunSunto-gun, JapanTaking people
- YokohamaYokohama, JapanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AstraZeneca
- Trial code
- NCT06129864
- Record updated
- 30 September 2026
- Original description
The main purpose of this study is to assess the efficacy and safety of volrustomig compared to observation in participants with unresected locally advanced head and neck squamous cell carcinoma (LA-HNSCC) who have not progressed after receiving definitive concurrent chemoradiotherapy (cCRT).Read full original descriptionShow less
A Phase III, Randomized, Open-Label, Multi-Center, Global Study of Volrustomig (MEDI5752) as Sequential Therapy Versus Observation in Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma, Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC)
The main purpose of this study is to assess the efficacy and safety of volrustomig compared to observation in participants with unresected locally advanced head and neck squamous cell carcinoma (LA-HNSCC) who have not progressed after receiving definitive concurrent chemoradiotherapy (cCRT).
Inclusion: Histologically or cytologically documented locally advanced squamous cell carcinoma of the oropharynx, hypopharynx, oral cavity, or larynx with no evidence of metastatic disease (i.e. M0); Confirmed unresected Stage III, Stage IVA or IVB according to the eighth edition of the American Joint Committee on Cancer (AJCC) staging manual (tumor, node, metastasis (TNM) staging system); Participants will have completed definitive concurrent chemoradiotherapy (cCRT) with curative intent prior to randomization.
Exclusion: Participants who have received radiotherapy (RT) alone as definitive local therapy for LA-HNSCC; Histologically/cytologically confirmed head and neck cancer of any other primary anatomic location in the head and neck not specified in the inclusion criteria including participants with squamous cell carcinoma of unknown primary or non-squamous histologies (eg, nasopharynx or salivary gland). Participants with >1 primary tumors are not eligible for the study; Participants with any of the following:; LA-HNSCC that was resected before definitive cCRT; LA-HNSCC that was treated and is recurrent at the time of screening.